ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook

The latest update is out from ANI Pharmaceuticals ( (ANIP) ).

On January 12, 2026, ANI Pharmaceuticals reported strong preliminary, unaudited results for 2025, highlighting that total net revenues, adjusted non-GAAP EBITDA and adjusted non-GAAP diluted EPS are expected to meet or exceed prior guidance, with Cortrophin Gel net revenues rising 76% year over year to about $347.8 million and ILUVIEN and YUTIQ contributing $74.9 million. The company, which ended 2025 with roughly $285 million in unrestricted cash, projected further acceleration in 2026 with total net revenues guided to $1.055 billion–$1.115 billion, adjusted non-GAAP EBITDA of $275 million–$290 million, and rare disease products expected to account for about 60% of sales, underpinned by a 55%–65% revenue surge in Cortrophin Gel. To support this growth and reinforce its transition into a leading rare disease player, ANI plans a roughly 90-person expansion of its rare disease organization by mid-2026 to capitalize on the acute gouty arthritis flare opportunity, continue investment in a Phase 4 trial for Cortrophin Gel, return ILUVIEN to growth, maintain 10–15 new generic launches annually, and pursue disciplined capital allocation aimed at scaling its rare disease business while sustaining cash generation from generics.

The most recent analyst rating on (ANIP) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

Spark’s Take on ANIP Stock

According to Spark, TipRanks’ AI Analyst, ANIP is a Neutral.

ANI Pharmaceuticals’ strong earnings call performance and revenue growth are significant positives, but challenges in profitability and high valuation metrics weigh on the overall score. Technical indicators suggest bearish momentum, adding caution to the outlook.

To see Spark’s full report on ANIP stock, click here.

More about ANI Pharmaceuticals

ANI Pharmaceuticals is a U.S.-based specialty pharmaceutical company listed on Nasdaq that operates across a high-growth Rare Disease franchise and a Generics and Brands business. Its key products include Purified Cortrophin Gel, an ACTH-based therapy with multiple indications including a unique position in acute gouty arthritis flares, and ophthalmic drugs ILUVIEN and YUTIQ, with a strategy centered on expanding its rare disease portfolio while using its generics platform and U.S. manufacturing footprint to generate cash and support R&D-driven growth.

Average Trading Volume: 411,983

Technical Sentiment Signal: Buy

Current Market Cap: $1.71B

For an in-depth examination of ANIP stock, go to TipRanks’ Overview page.